QIAGEN N V : QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Debido a la alta demanda y a los cupos establecidos en nueve unidades académicas, 7 mil 600 estudiantes presentarán la Prueba de Ubicación del Nivel Medio Su
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
(0)
The therascreen KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS
TM (sotorasib) from Amgen
KRAS G12C mutation in NSCLC
Test will be available under QIAGEN s Day One Lab Readiness program
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the
therascreen KRAS RGQ PCR Kit (
therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRAS
QIAGEN N.V.: QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Mirati s investigational selective KRAS
G12C inhibitor
Program adds to QIAGEN s strong position in KRAS companion diagnostic testing in NSCLC
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRAS
G12C mutation who may benefit from treatment with
adagrasib, Mirati s investigational, highly selective and potent oral small molecule inhibitor of KRAS